[{"id":"4e3eec72-a814-4c0e-9cb1-d5be450dc993","acronym":"BEAMION-Lung 1","url":"https://clinicaltrials.gov/study/NCT04886804","created_at":"2021-05-14T12:52:37.162Z","updated_at":"2025-02-25T15:35:04.451Z","phase":"Phase 1","brief_title":"Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)","source_id_and_acronym":"NCT04886804 - BEAMION-Lung 1","lead_sponsor":"Boehringer Ingelheim","biomarkers":" NRG1","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 mutation","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hernexeos (zongertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 554","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 01/28/2028","study_completion_date":" 01/28/2028","last_update_posted":"2025-02-10"}]